After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...